Medpace Holdings Class Action Lawsuit Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: PRnewswire
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, or risk losing their right to compensation in the class action lawsuit.
- Fee Arrangement: Investors can participate in the class action without any upfront costs, as attorney fees will be covered through a contingency fee arrangement, significantly lowering the financial barrier for investors seeking compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations, which resulted in losses when the true situation was revealed, negatively impacting the company's reputation and stock price.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and recovering hundreds of millions for investors, showcasing its expertise and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 428.000
Low
462.00
Averages
569.17
High
660.00
Current: 428.000
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws, concerning securities transactions between April 22, 2025, and February 9, 2026, with a deadline for investor contact set for June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which resulted in investor losses once the market learned the truth, highlighting serious deficiencies in the company's transparency and integrity.
- Legal Proceedings Status: The class action has not yet been certified by the court, meaning investors are not represented by an attorney during this period, and those who choose not to act will remain absent class members, potentially jeopardizing their claims.
- Investor Rights Protection: The Schall Law Firm specializes in securities class actions and encourages affected investors to reach out to discuss their rights, demonstrating a commitment to protecting investor interests and aiming to assist them in recovering losses.
See More
Multiple Companies Face Class Action Lawsuits
- Gossamer Bio Lawsuit: Gossamer Bio is facing allegations for failing to disclose critical facts regarding the failure of its clinical trial from June 16, 2025, to February 20, 2026, which misled investors about the company's prospects, potentially impacting stock prices and investor confidence.
- New Era Energy Issues: New Era Energy is accused of overstating progress on its Texas data center project and engaging in fraudulent activities from November 6, 2024, to December 29, 2025, which could lead to severe misjudgments of the company's financial health, affecting its market performance.
- Medpace Holdings Allegations: Medpace Holdings is under scrutiny for allegedly inflating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of order cancellations from April 22, 2025, to February 9, 2026, which may undermine investor confidence in the company's future growth.
- Legal Consultation Opportunity: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to file a lead plaintiff motion by the deadlines to protect their rights and seek legal recourse.
See More
Reminder for Medpace Investors on Class Action Deadline
- Lawsuit Background: Investors are reminded to file a lead plaintiff motion by June 8, 2026, concerning those who purchased Medpace stock between April 22, 2025, and February 9, 2026, highlighting investor concerns over the company's financial performance.
- Financial Miss: Medpace's Q4 2025 financial results released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the expected 1.15, primarily due to backlog cancellations reaching the highest level in over a year, resulting in a 15.9% drop in stock price the following day.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts affecting its business and prospects, harming investor interests.
- Investor Losses: The failure to meet the projected book-to-bill ratio has led to significant losses for investors following the stock price decline, with the lawsuit aiming to seek compensation for affected investors.
See More
Medpace Holdings Class Action Lawsuit Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, or risk losing their right to compensation in the class action lawsuit.
- Fee Arrangement: Investors can participate in the class action without any upfront costs, as attorney fees will be covered through a contingency fee arrangement, significantly lowering the financial barrier for investors seeking compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations, which resulted in losses when the true situation was revealed, negatively impacting the company's reputation and stock price.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and recovering hundreds of millions for investors, showcasing its expertise and resource advantages in handling such cases.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace Holdings, Inc., involving investors who purchased shares between April 22, 2025, and February 9, 2026, alleging that the company made false and misleading statements that artificially inflated its stock price during this period.
- Investor Losses: The complaint indicates that Medpace's misrepresentations became evident through poor performance throughout the class period, resulting in significant losses for investors once the truth was revealed, highlighting the company's damaged reputation in the market.
- Legal Process: Investors are required to apply by June 5, 2026, to be appointed as lead plaintiffs in the lawsuit, underscoring the urgency and impact of this case on affected investors.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities litigation for individual and institutional investors, demonstrating its expertise and influence in the field of securities law.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record and resources in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, avoiding firms that act merely as intermediaries, and instead choose attorneys with proven success in securities class actions to ensure their rights are effectively protected.
See More
Medpace Holdings Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Medpace Holdings (NASDAQ:MEDP) for violations of securities laws, concerning securities transactions between April 22, 2025, and February 9, 2026, with a deadline for investor contact set for June 5, 2026.
- False Statement Allegations: The complaint alleges that Medpace made false and misleading statements during the class period, artificially inflating its stock price, which resulted in investor losses once the market learned the truth, highlighting serious deficiencies in the company's transparency and integrity.
- Legal Proceedings Status: The class action has not yet been certified by the court, meaning investors are not represented by an attorney during this period, and those who choose not to act will remain absent class members, potentially jeopardizing their claims.
- Investor Rights Protection: The Schall Law Firm specializes in securities class actions and encourages affected investors to reach out to discuss their rights, demonstrating a commitment to protecting investor interests and aiming to assist them in recovering losses.
See More
Multiple Companies Face Class Action Lawsuits
- Gossamer Bio Lawsuit: Gossamer Bio is facing allegations for failing to disclose critical facts regarding the failure of its clinical trial from June 16, 2025, to February 20, 2026, which misled investors about the company's prospects, potentially impacting stock prices and investor confidence.
- New Era Energy Issues: New Era Energy is accused of overstating progress on its Texas data center project and engaging in fraudulent activities from November 6, 2024, to December 29, 2025, which could lead to severe misjudgments of the company's financial health, affecting its market performance.
- Medpace Holdings Allegations: Medpace Holdings is under scrutiny for allegedly inflating its projected book-to-bill ratio for Q4 2025 and failing to adequately assess the impact of order cancellations from April 22, 2025, to February 9, 2026, which may undermine investor confidence in the company's future growth.
- Legal Consultation Opportunity: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to file a lead plaintiff motion by the deadlines to protect their rights and seek legal recourse.
See More
Reminder for Medpace Investors on Class Action Deadline
- Lawsuit Background: Investors are reminded to file a lead plaintiff motion by June 8, 2026, concerning those who purchased Medpace stock between April 22, 2025, and February 9, 2026, highlighting investor concerns over the company's financial performance.
- Financial Miss: Medpace's Q4 2025 financial results released on February 9, 2026, revealed a book-to-bill ratio of 1.04, significantly below the expected 1.15, primarily due to backlog cancellations reaching the highest level in over a year, resulting in a 15.9% drop in stock price the following day.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements and failed to disclose adverse facts affecting its business and prospects, harming investor interests.
- Investor Losses: The failure to meet the projected book-to-bill ratio has led to significant losses for investors following the stock price decline, with the lawsuit aiming to seek compensation for affected investors.
See More
Medpace Holdings Class Action Lawsuit Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, that they must apply to be lead plaintiff by June 8, 2026, or risk losing their right to compensation in the class action lawsuit.
- Fee Arrangement: Investors can participate in the class action without any upfront costs, as attorney fees will be covered through a contingency fee arrangement, significantly lowering the financial barrier for investors seeking compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false or misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations, which resulted in losses when the true situation was revealed, negatively impacting the company's reputation and stock price.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and recovering hundreds of millions for investors, showcasing its expertise and resource advantages in handling such cases.
See More
Class Action Lawsuit Filed Against Medpace Holdings, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Medpace Holdings, Inc., involving investors who purchased shares between April 22, 2025, and February 9, 2026, alleging that the company made false and misleading statements that artificially inflated its stock price during this period.
- Investor Losses: The complaint indicates that Medpace's misrepresentations became evident through poor performance throughout the class period, resulting in significant losses for investors once the truth was revealed, highlighting the company's damaged reputation in the market.
- Legal Process: Investors are required to apply by June 5, 2026, to be appointed as lead plaintiffs in the lawsuit, underscoring the urgency and impact of this case on affected investors.
- Law Firm Overview: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities litigation for individual and institutional investors, demonstrating its expertise and influence in the field of securities law.
See More
Reminder for Medpace Stock Class Action Lawsuit
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates during the class period, leading investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record and resources in this field.
- Investor Advisory: Investors are advised to carefully select legal counsel, avoiding firms that act merely as intermediaries, and instead choose attorneys with proven success in securities class actions to ensure their rights are effectively protected.
See More
